Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANOII

Financiado

Cerrado

Nanoscopically guided induction and expansion of regulatory hematopoietic cells...

Nanoscopically guided induction and expansion of regulatory hematopoietic cells to treat autoimmune and inflammatory processes We propose a multidisciplinary program, focusing on the development of novel approaches for directing the differentiation, proliferation and tissue-tropism of specific hematopoietic lineages, using micro- and nano-fabricated cell... ver más

30/11/2013

MPG

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 15 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-11-30 No tenemos la información de la convocatoria

0% 72% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

15 Participantes

MPG

0.00€ | Lider

CHALMERS TEKNISKA HOGSKOLA A...

N.D. | Participante

EVCYT

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

UNBIAS Nanobodies to prevent hematopoietic stem cell bias and hyper... Cerrado

VASTO VAScularised Tumour Organoids on a chip with human placenta... 150K€ Cerrado

PHOENIX NANOMEDICINE FOR ORGAN TRANSPLANTATION TOLERANCE (PHOENIX) 5M€ Cerrado

DPI2017-90058-R SUPERFICIES NANOESTRUCTURADAS BIOFUNCIONALES COMO NUEVA GENE... 177K€ Cerrado

SciFiMed Screening of inFlammation to enable personalized Medicine 4M€ Cerrado

DOMES Directed Orchestration of Microfluidic Environments for guid... 150K€ Cerrado

Líder del proyecto

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto We propose a multidisciplinary program, focusing on the development of novel approaches for directing the differentiation, proliferation and tissue-tropism of specific hematopoietic lineages, using micro- and nano-fabricated cell chips. We will use advanced nanofabricated surfaces functionalized with specific biomolecules, and microfluidics cell chips to specify and expend regulatory immune cells for treating diverse inflammatory and autoimmune disorders in an organ- and antigen-specific manner. The proposed cell-chip will create ex-vivo microenvironments mimicking in-vivo cell-cell interactions and molecular signals involved in differentiation and proliferation of hematopoietic cells. Cell chip development and optimization will be supported by high throughput microscopy to select for optimal conditions. Educated cells will be employed for in vivo experiments in mice and the methodology will be further adapted for human cell populations, and applied for clinical diagnosis and therapy as well as the developments of clinically-relevant devices. Regulatory T-cells are extremely promising cells for treatment of inflammatory and auto-immune disease, as well as for tolerance induction in organ transplantation. To be effective they must be produced conveniently, at large numbers with an optimally tuned phenotype. The methodology is suggested to overcome current obstacles in obtaining therapeutically significant numbers of T cells. We propose to apply the suggested methodology for treating different inflammatory or autoimmune diseases including type-1 diabetes using targeted immunotherapeutic approaches. Developing new methods for producing large numbers of finely-tuned and tissue-targeted regulatory cells will make this approach clinically viable. This novel methodology can be extended to directing differentiation of other specific T-cell and hematopoietic lineages, with possible applications for targeting other autoimmune diseases and treating tumors or graft rejection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores